Brach M A, Herrmann F, Yamada H, Bäuerle P A, Kufe D W
Laboratory of Clinical Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
EMBO J. 1992 Apr;11(4):1479-86. doi: 10.1002/j.1460-2075.1992.tb05192.x.
In this study we report the identification of a novel transcription factor, termed Nuclear Factor-jun (NF-jun). This factor contributes to inducible transcription of the c-jun gene in human myeloid leukemia cells. NF-jun was, however, undetectable in nuclear proteins from human monocytes, granulocytes, resting T lymphocytes and lung fibroblasts. NF-jun shares several features with the well characterized NF-kappa B in that binding activity can be generated in cytosolic extracts by treatment with dissociating agents. In addition, binding of NF-jun to its recognition site is enhanced by treatment of cells with 12-O-tetradecanoylphorbol-13-acetate, tumor necrosis factor alpha or the protein synthesis inhibitor cycloheximide (CHX). However, as revealed by competition assays and electrophoretic mobility shift assays, purified NF-kappa B fails to bind to the c-jun fragment which contains the NF-jun site, and this fragment fails to compete with NF-kappa B for binding. UV crosslinking showed that NF-jun contains a 55 and a 125 kDa protein species. These findings demonstrate that the c-jun gene can be regulated by a transcription factor distinct from AP-1. Our findings also indicate that while NF-jun has several features in common with the NF-kappa B binding protein including its subcellular localization and its ability to translocate from the cytoplasm to the nucleus, this factor recognizes a unique DNA sequence. Moreover, the activity of this protein is differentially regulated in various cell types. NF-jun might function as a signal transducing molecule in order to mediate rapid induction of the early response gene c-jun in a cell type- and stimulus-specific manner.
在本研究中,我们报告了一种新型转录因子的鉴定,该因子被称为核因子-jun(NF-jun)。这种因子有助于人类髓系白血病细胞中c-jun基因的诱导性转录。然而,在人类单核细胞、粒细胞、静息T淋巴细胞和肺成纤维细胞的核蛋白中未检测到NF-jun。NF-jun与特征明确的NF-κB具有若干共同特征,即通过用解离剂处理可在胞质提取物中产生结合活性。此外,用12-O-十四烷酰佛波醇-13-乙酸酯、肿瘤坏死因子α或蛋白质合成抑制剂环己酰亚胺(CHX)处理细胞可增强NF-jun与其识别位点的结合。然而,竞争分析和电泳迁移率变动分析表明,纯化的NF-κB无法与含有NF-jun位点的c-jun片段结合,且该片段无法与NF-κB竞争结合。紫外线交联显示NF-jun包含55 kDa和125 kDa的蛋白种类。这些发现表明,c-jun基因可由一种不同于AP-1的转录因子调控。我们的发现还表明,虽然NF-jun与NF-κB结合蛋白有若干共同特征,包括其亚细胞定位及其从细胞质转运至细胞核的能力,但该因子识别独特的DNA序列。此外,这种蛋白的活性在不同细胞类型中受到差异调节。NF-jun可能作为一种信号转导分子,以便以细胞类型和刺激特异性的方式介导早期反应基因c-jun的快速诱导。